Literature DB >> 10561756

A prospective study of infections with atypical pneumonia organisms in acute exacerbations of chronic bronchitis.

S K Goh1, A Johan, T H Cheong, Y T Wang.   

Abstract

The objective of this paper was to study the incidence of 6 atypical pneumonia pathogens or atypical organisms in local patients admitted for acute exacerbation of chronic bronchitis. This is a prospective observational study. Over a period of 3 years (1995 to 1997), 90 patients admitted to a large general hospital in Singapore for acute exacerbation of chronic bronchitis were tested for the following infections: Legionella, Mycoplasma, Chlamydia, influenza A, influenza B and parainfluenza viruses, using paired serological examination. The antibiotic prescribing pattern by the attending physicians in these cases were also examined. Positive serologies were found in 31 patients (34%), of whom 26 patients (28%) had viral infections. The most common organism was influenza A with 18 positive serologies (20%). Five patients were tested positive for Legionella. There was no evidence of acute infections by Mycoplasma pneumoniae or chlamydia using serological tests.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10561756

Source DB:  PubMed          Journal:  Ann Acad Med Singapore        ISSN: 0304-4602            Impact factor:   2.473


  2 in total

1.  Relationship Among Chlamydia and Mycoplasma Pneumoniae Seropositivity, IKZF1 Genotype and Chronic Obstructive Pulmonary Disease in A General Japanese Population: The Nagahama Study.

Authors:  Shigeo Muro; Yasuharu Tabara; Hisako Matsumoto; Kazuya Setoh; Takahisa Kawaguchi; Meiko Takahashi; Isao Ito; Yutaka Ito; Kimihiko Murase; Chikashi Terao; Shinji Kosugi; Ryo Yamada; Akihiro Sekine; Takeo Nakayama; Kazuo Chin; Michiaki Mishima; Fumihiko Matsuda
Journal:  Medicine (Baltimore)       Date:  2016-04       Impact factor: 1.889

Review 2.  The chronic obstructive pulmonary disease exacerbation.

Authors:  P A Sherk; R F Grossman
Journal:  Clin Chest Med       Date:  2000-12       Impact factor: 2.878

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.